Acute renal failure has been observed in patients undergoing treatment with VFEND. Patients being treated with voriconazole are likely to be treated concomitantly with nephrotoxic medications and may have concurrent conditions that may result in decreased renal function.
Patients should be monitored for the development of abnormal renal function. This should include laboratory evaluation of serum creatinine [see Clinical Pharmacology (12.3) and Dosage and Administration (2.6)].
Reversible cases of azole-induced adrenal insufficiency have been reported in patients receiving azoles, including VFEND. Adrenal insufficiency has been reported in patients receiving azoles with or without concomitant corticosteroids. In patients receiving azoles without corticosteroids adrenal insufficiency is related to direct inhibition of steroidogenesis by azoles. In patients taking corticosteroids, voriconazole associated CYP3A4 inhibition of their metabolism may lead to corticosteroid excess and adrenal suppression [see Drug Interactions (7) and Clinical Pharmacology (12.3)]. Cushing’s syndrome with and without subsequent adrenal insufficiency has also been reported in patients receiving VFEND concomitantly with corticosteroids.
Patients receiving VFEND and corticosteroids (via all routes of administration) should be carefully monitored for adrenal dysfunction both during and after VFEND treatment. Patients should be instructed to seek immediate medical care if they develop signs and symptoms of Cushing’s syndrome or adrenal insufficiency.
Voriconazole can cause fetal harm when administered to a pregnant woman.
In animals, voriconazole administration was associated with fetal malformations, embryotoxicity, increased gestational length, dystocia and embryomortality [see Use in Specific Populations (8.1)].
If VFEND is used during pregnancy, or if the patient becomes pregnant while taking VFEND, inform the patient of the potential hazard to the fetus. Advise females of reproductive potential to use effective contraception during treatment with VFEND [see Use in Specific Populations (8.3)].
Electrolyte disturbances such as hypokalemia, hypomagnesemia and hypocalcemia should be corrected prior to initiation of and during VFEND therapy.
Patient management should include laboratory evaluation of renal (particularly serum creatinine) and hepatic function (particularly liver function tests and bilirubin).
Pancreatitis has been observed in patients undergoing treatment with VFEND [see Adverse Reactions (6.1, 6.2)] Patients with risk factors for acute pancreatitis (e.g., recent chemotherapy, hematopoietic stem cell transplantation [HSCT]) should be monitored for the development of pancreatitis during VFEND treatment.
Fluorosis and periostitis have been reported during long-term VFEND therapy. If a patient develops skeletal pain and radiologic findings compatible with fluorosis or periostitis, VFEND should be discontinued [see Adverse Reactions (6.2)].
See Table 10 for a listing of drugs that may significantly alter voriconazole concentrations. Also, see Table 11 for a listing of drugs that may interact with voriconazole resulting in altered pharmacokinetics or pharmacodynamics of the other drug [see Contraindications (4) and Drug Interactions (7)].
The following serious adverse reactions are described elsewhere in the labeling:
Hepatic Toxicity [see Warnings and Precautions (5.1)]
Arrhythmias and QT Prolongation [see Warnings and Precautions (5.2)]
Infusion Related Reactions [see Warnings and Precautions (5.3)]
Visual Disturbances [see Warnings and Precautions (5.4)]
Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.5)]
Photosensitivity [see Warnings and Precautions (5.6)]
Renal Toxicity [see Warnings and Precautions (5.7)]
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Clinical Trials Experience in Adults
The most frequently reported adverse reactions (see Table 4) in the adult therapeutic trials were visual disturbances (18.7%), fever (5.7%), nausea (5.4%), rash (5.3%), vomiting (4.4%), chills (3.7%), headache (3.0%), liver function test increased (2.7%), tachycardia (2.4%), hallucinations (2.4%). The adverse reactions which most often led to discontinuation of voriconazole therapy were elevated liver function tests, rash, and visual disturbances [see Warning and Precautions (5.1, 5.4) and Adverse Reactions (6.1)].
The data described in Table 4 reflect exposure to voriconazole in 1655 patients in nine therapeutic studies. This represents a heterogeneous population, including immunocompromised patients, e.g., patients with hematological malignancy or HIV and non-neutropenic patients. This subgroup does not include healthy subjects and patients treated in the compassionate use and non-therapeutic studies. This patient population was 62% male, had a mean age of 46 years (range 11–90, including 51 patients aged 12–18 years), and was 78% White and 10% Black. Five hundred sixty one patients had a duration of voriconazole therapy of greater than 12 weeks, with 136 patients receiving voriconazole for over six months. Table 4 includes all adverse reactions which were reported at an incidence of ≥2% during voriconazole therapy in the all therapeutic studies population, studies 307/602 and 608 combined, or study 305, as well as events of concern which occurred at an incidence of <2%.
In study 307/602, 381 patients (196 on voriconazole, 185 on amphotericin B) were treated to compare voriconazole to amphotericin B followed by other licensed antifungal therapy (OLAT) in the primary treatment of patients with acute IA. The rate of discontinuation from voriconazole study medication due to adverse reactions was 21.4% (42/196 patients). In study 608, 403 patients with candidemia were treated to compare voriconazole (272 patients) to the regimen of amphotericin B followed by fluconazole (131 patients). The rate of discontinuation from voriconazole study medication due to adverse reactions was 19.5% out of 272 patients. Study 305 evaluated the effects of oral voriconazole (200 patients) and oral fluconazole (191 patients) in the treatment of EC. The rate of discontinuation from voriconazole study medication in Study 305 due to adverse reactions was 7% (14/200 patients). Laboratory test abnormalities for these studies are discussed under Clinical Laboratory Values below.
|Therapeutic Studies †||Studies 307/602 and 608(IV/ oral therapy)||Study 305(oral therapy)|
|VoriconazoleN=1655||VoriconazoleN=468||Ampho B ‡N=185||Ampho B→ FluconazoleN=131||VoriconazoleN=200||FluconazoleN=191|
|N (%)||N (%)||N (%)||N (%)||N (%)||N (%)|
|Special Senses §|
|Abnormal vision||310 (18.7)||63 (13.5)||1 (0.5)||0||31 (15.5)||8 (4.2)|
|Photophobia||37 (2.2)||8 (1.7)||0||0||5 (2.5)||2 (1.0)|
|Chromatopsia||20 (1.2)||2 (0.4)||0||0||2 (1.0)||0|
|Body as a Whole|
|Fever||94 (5.7)||8 (1.7)||25 (13.5)||5 (3.8)||0||0|
|Chills||61 (3.7)||1 (0.2)||36 (19.5)||8 (6.1)||1 (0.5)||0|
|Headache||49 (3.0)||9 (1.9)||8 (4.3)||1 (0.8)||0||1 (0.5)|
|Tachycardia||39 (2.4)||6 (1.3)||5 (2.7)||0||0||0|
|Nausea||89 (5.4)||18 (3.8)||29 (15.7)||2 (1.5)||2 (1.0)||3 (1.6)|
|Vomiting||72 (4.4)||15 (3.2)||18 (9.7)||1 (0.8)||2 (1.0)||1 (0.5)|
|Liver function tests abnormal||45 (2.7)||15 (3.2)||4 (2.2)||1 (0.8)||6 (3.0)||2 (1.0)|
|Cholestatic jaundice||17 (1.0)||8 (1.7)||0||1 (0.8)||3 (1.5)||0|
|Metabolic and Nutritional Systems|
|Alkaline phosphatase increased||59 (3.6)||19 (4.1)||4 (2.2)||3 (2.3)||10 (5.0)||3 (1.6)|
|Hepatic enzymes increased||30 (1.8)||11 (2.4)||5 (2.7)||1 (0.8)||3 (1.5)||0|
|SGOT increased||31 (1.9)||9 (1.9)||0||1 (0.8)||8 (4.0)||2 (1.0)|
|SGPT increased||29 (1.8)||9 (1.9)||1 (0.5)||2 (1.5)||6 (3.0)||2 (1.0)|
|Hypokalemia||26 (1.6)||3 (0.6)||36 (19.5)||16 (12.2)||0||0|
|Bilirubinemia||15 (0.9)||5 (1.1)||3 (1.6)||2 (1.5)||1 (0.5)||0|
|Creatinine increased||4 (0.2)||0||59 (31.9)||10 (7.6)||1 (0.5)||0|
|Hallucinations||39 (2.4)||13 (2.8)||1 (0.5)||0||0||0|
|Skin and Appendages|
|Rash||88 (5.3)||20 (4.3)||7 (3.8)||1 (0.8)||3 (1.5)||1 (0.5)|
|Kidney function abnormal||10 (0.6)||6 (1.3)||40 (21.6)||9 (6.9)||1 (0.5)||1 (0.5)|
|Acute kidney failure||7 (0.4)||2 (0.4)||11 (5.9)||7 (5.3)||0||0|
VFEND treatment-related visual disturbances are common. In therapeutic trials, approximately 21% of patients experienced abnormal vision, color vision change and/or photophobia. Visual disturbances may be associated with higher plasma concentrations and/or doses.
The mechanism of action of the visual disturbance is unknown, although the site of action is most likely to be within the retina. In a study in healthy subjects investigating the effect of 28-day treatment with voriconazole on retinal function, VFEND caused a decrease in the electroretinogram (ERG) waveform amplitude, a decrease in the visual field, and an alteration in color perception. The ERG measures electrical currents in the retina. These effects were noted early in administration of VFEND and continued through the course of study drug treatment. Fourteen days after the end of dosing, ERG, visual fields and color perception returned to normal [see Warnings and Precautions (5.4)].
Dermatological reactions were common in patients treated with VFEND. The mechanism underlying these dermatologic adverse reactions remains unknown.
Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported during treatment with VFEND. Erythema multiforme has also been reported during treatment with VFEND [see Warnings and Precautions (5.5) and Adverse Reactions (6.2)].
VFEND has also been associated with additional photosensitivity related skin reactions such as pseudoporphyria, cheilitis, and cutaneous lupus erythematosus [see Warnings and Precautions (5.6)].
Less Common Adverse Reactions
The following adverse reactions occurred in <2% of all voriconazole-treated patients in all therapeutic studies (N=1655). This listing includes events where a causal relationship to voriconazole cannot be ruled out or those which may help the physician in managing the risks to the patients. The list does not include events included in Table 4 above and does not include every event reported in the voriconazole clinical program.
Body as a Whole: abdominal pain, abdomen enlarged, allergic reaction, anaphylactoid reaction [see Warnings and Precautions (5.3)] , ascites, asthenia, back pain, chest pain, cellulitis, edema, face edema, flank pain, flu syndrome, graft versus host reaction, granuloma, infection, bacterial infection, fungal infection, injection site pain, injection site infection/inflammation, mucous membrane disorder, multi-organ failure, pain, pelvic pain, peritonitis, sepsis, substernal chest pain.
Cardiovascular: atrial arrhythmia, atrial fibrillation, AV block complete, bigeminy, bradycardia, bundle branch block, cardiomegaly, cardiomyopathy, cerebral hemorrhage, cerebral ischemia, cerebrovascular accident, congestive heart failure, deep thrombophlebitis, endocarditis, extrasystoles, heart arrest, hypertension, hypotension, myocardial infarction, nodal arrhythmia, palpitation, phlebitis, postural hypotension, pulmonary embolus, QT interval prolonged, supraventricular extrasystoles, supraventricular tachycardia, syncope, thrombophlebitis, vasodilatation, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia (including torsade de pointes) [see Warnings and Precautions (5.2) ].
Digestive: anorexia, cheilitis, cholecystitis, cholelithiasis, constipation, diarrhea, duodenal ulcer perforation, duodenitis, dyspepsia, dysphagia, dry mouth, esophageal ulcer, esophagitis, flatulence, gastroenteritis, gastrointestinal hemorrhage, GGT/LDH elevated, gingivitis, glossitis, gum hemorrhage, gum hyperplasia, hematemesis, hepatic coma, hepatic failure, hepatitis, intestinal perforation, intestinal ulcer, jaundice, enlarged liver, melena, mouth ulceration, pancreatitis, parotid gland enlargement, periodontitis, proctitis, pseudomembranous colitis, rectal disorder, rectal hemorrhage, stomach ulcer, stomatitis, tongue edema.
Endocrine: adrenal cortex insufficiency, diabetes insipidus, hyperthyroidism, hypothyroidism.
Hemic and Lymphatic: agranulocytosis, anemia (macrocytic, megaloblastic, microcytic, normocytic), aplastic anemia, hemolytic anemia, bleeding time increased, cyanosis, DIC, ecchymosis, eosinophilia, hypervolemia, leukopenia, lymphadenopathy, lymphangitis, marrow depression, pancytopenia, petechia, purpura, enlarged spleen, thrombocytopenia, thrombotic thrombocytopenic purpura.
Metabolic and Nutritional: albuminuria, BUN increased, creatine phosphokinase increased, edema, glucose tolerance decreased, hypercalcemia, hypercholesteremia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hyperuricemia, hypocalcemia, hypoglycemia, hypomagnesemia, hyponatremia, hypophosphatemia, peripheral edema, uremia.
Musculoskeletal: arthralgia, arthritis, bone necrosis, bone pain, leg cramps, myalgia, myasthenia, myopathy, osteomalacia, osteoporosis.
Nervous System: abnormal dreams, acute brain syndrome, agitation, akathisia, amnesia, anxiety, ataxia, brain edema, coma, confusion, convulsion, delirium, dementia, depersonalization, depression, diplopia, dizziness, encephalitis, encephalopathy, euphoria, Extrapyramidal Syndrome, grand mal convulsion, Guillain-Barré syndrome, hypertonia, hypesthesia, insomnia, intracranial hypertension, libido decreased, neuralgia, neuropathy, nystagmus, oculogyric crisis, paresthesia, psychosis, somnolence, suicidal ideation, tremor, vertigo.
Respiratory System: cough increased, dyspnea, epistaxis, hemoptysis, hypoxia, lung edema, pharyngitis, pleural effusion, pneumonia, respiratory disorder, respiratory distress syndrome, respiratory tract infection, rhinitis, sinusitis, voice alteration.
Skin and Appendages: alopecia, angioedema, contact dermatitis, discoid lupus erythematosis, eczema, erythema multiforme, exfoliative dermatitis, fixed drug eruption, furunculosis, herpes simplex, maculopapular rash, melanoma, melanosis, photosensitivity skin reaction, pruritus, pseudoporphyria, psoriasis, skin discoloration, skin disorder, skin dry, Stevens-Johnson syndrome, squamous cell carcinoma, sweating, toxic epidermal necrolysis, urticaria.
Special Senses: abnormality of accommodation, blepharitis, color blindness, conjunctivitis, corneal opacity, deafness, ear pain, eye pain, eye hemorrhage, dry eyes, hypoacusis, keratitis, keratoconjunctivitis, mydriasis, night blindness, optic atrophy, optic neuritis, otitis externa, papilledema, retinal hemorrhage, retinitis, scleritis, taste loss, taste perversion, tinnitus, uveitis, visual field defect.
Urogenital: anuria, blighted ovum, creatinine clearance decreased, dysmenorrhea, dysuria, epididymitis, glycosuria, hemorrhagic cystitis, hematuria, hydronephrosis, impotence, kidney pain, kidney tubular necrosis, metrorrhagia, nephritis, nephrosis, oliguria, scrotal edema, urinary incontinence, urinary retention, urinary tract infection, uterine hemorrhage, vaginal hemorrhage.
Clinical Laboratory Values in Adults
The overall incidence of transaminase increases >3× upper limit of normal (not necessarily comprising an adverse reaction) was 17.7% (268/1514) in adult subjects treated with VFEND for therapeutic use in pooled clinical trials. Increased incidence of liver function test abnormalities may be associated with higher plasma concentrations and/or doses. The majority of abnormal liver function tests either resolved during treatment without dose adjustment or resolved following dose adjustment, including discontinuation of therapy.
VFEND has been infrequently associated with cases of serious hepatic toxicity including cases of jaundice and rare cases of hepatitis and hepatic failure leading to death. Most of these patients had other serious underlying conditions.
Liver function tests should be evaluated at the start of and during the course of VFEND therapy. Patients who develop abnormal liver function tests during VFEND therapy should be monitored for the development of more severe hepatic injury. Patient management should include laboratory evaluation of hepatic function (particularly liver function tests and bilirubin). Discontinuation of VFEND must be considered if clinical signs and symptoms consistent with liver disease develop that may be attributable to VFEND [see Warnings and Precautions (5.1)].
Acute renal failure has been observed in severely ill patients undergoing treatment with VFEND. Patients being treated with VFEND are likely to be treated concomitantly with nephrotoxic medications and may have concurrent conditions that can result in decreased renal function. It is recommended that patients are monitored for the development of abnormal renal function. This should include laboratory evaluation of serum creatinine.
Tables 5 to 7 show the number of patients with hypokalemia and clinically significant changes in renal and liver function tests in three randomized, comparative multicenter studies. In study 305, patients with EC were randomized to either oral VFEND or oral fluconazole. In study 307/602, patients with definite or probable IA were randomized to either VFEND or amphotericin B therapy. In study 608, patients with candidemia were randomized to either VFEND or the regimen of amphotericin B followed by fluconazole.
|n/N (%)||n/N (%)|
|n = number of patients with a clinically significant abnormality while on study therapy N = total number of patients with at least one observation of the given lab test while on study therapy AST = Aspartate aminotransferase; ALT= alanine aminotransferase ULN = upper limit of normal|
|T. Bilirubin||>1.5× ULN||8/185 (4.3)||7/186 (3.8)|
|AST||>3.0× ULN||38/187 (20.3)||15/186 (8.1)|
|ALT||>3.0× ULN||20/187 (10.7)||12/186 (6.5)|
|Alkaline Phosphatase||>3.0× ULN||19/187 (10.2)||14/186 (7.5)|
|Criteria *||Voriconazole||Amphotericin B †|
|n/N (%)||n/N (%)|
|n = number of patients with a clinically significant abnormality while on study therapy N = total number of patients with at least one observation of the given lab test while on study therapy AST = Aspartate aminotransferase; ALT= alanine aminotransferase ULN = upper limit of normal LLN = lower limit of normal|
|T. Bilirubin||>1.5× ULN||35/180 (19.4)||46/173 (26.6)|
|AST||>3.0× ULN||21/180 (11.7)||18/174 (10.3)|
|ALT||>3.0× ULN||34/180 (18.9)||40/173 (23.1)|
|Alkaline Phosphatase||>3.0× ULN||29/181 (16.0)||38/173 (22.0)|
|Creatinine||>1.3× ULN||39/182 (21.4)||102/177 (57.6)|
|Potassium||<0.9× LLN||30/181 (16.6)||70/178 (39.3)|
|Criteria *||Voriconazole||Amphotericin B followed by Fluconazole|
|n/N (%)||n/N (%)|
|n = number of patients with a clinically significant abnormality while on study therapy N = total number of patients with at least one observation of the given lab test while on study therapy AST = Aspartate aminotransferase; ALT = alanine aminotransferase ULN = upper limit of normal LLN = lower limit of normal|
|T. Bilirubin||>1.5× ULN||50/261 (19.2)||31/115 (27.0)|
|AST||>3.0× ULN||40/261 (15.3)||16/116 (13.8)|
|ALT||>3.0× ULN||22/261 (8.4)||15/116 (12.9)|
|Alkaline Phosphatase||>3.0× ULN||59/261 (22.6)||26/115 (22.6)|
|Creatinine||>1.3× ULN||39/260 (15.0)||32/118 (27.1)|
|Potassium||<0.9× LLN||43/258 (16.7)||35/118 (29.7)|
Clinical Trials Experience in Pediatric Patients
The safety of VFEND was investigated in 105 pediatric patients aged 2 to less than 18 years, including 52 pediatric patients less than 18 years of age who were enrolled in the adult therapeutic studies.
Serious Adverse Reactions and Adverse Reactions Leading to Discontinuation
In clinical studies, serious adverse reactions occurred in 46% (48/105) of VFEND treated pediatric patients. Treatment discontinuations due to adverse reactions occurred in 12 /105 (11%) of all patients. Hepatic adverse reactions (i.e. ALT increased; liver function test abnormal; jaundice) 6% (6/105) accounted for the majority of VFEND treatment discontinuations.
Most Common Adverse Reactions
The most common adverse reactions occurring in ≥5% of pediatric patients receiving VFEND in the pooled pediatric clinical trials are displayed by body system, in Table 8.
|Body System||Adverse Reaction||Pooled Pediatric Data *N=105n (%)|
|Abbreviations: ALT = alanine aminotransferase; LFT = liver function test|
|Blood and Lymphatic Systems Disorders||Thrombocytopenia||10 (10)|
|Cardiac Disorders||Tachycardia||7 (7)|
|Eye Disorders||Visual Disturbances †||27 (26)|
|Gastrointestinal Disorders||Vomiting||21 (20)|
|Abdominal pain ‡||13 (12)|
|Abdominal distention||5 (5)|
|General Disorders and Administration Site Conditions||Pyrexia||25 (25)|
|Peripheral edema||9 (9)|
|Mucosal inflammation||6 (6)|
|Infections and Infestations||Upper respiratory tract infection||5 (5)|
|Investigations||ALT abnormal §||9 (9)|
|LFT abnormal||6 (6)|
|Metabolism and Nutrition Disorders||Hypokalemia||11 (11)|
|Nervous System Disorders||Headache||10 (10)|
|Psychiatric Disorders||Hallucinations ¶||5 (5)|
|Renal and Urinary Disorders||Renal impairment #||5 (5)|
|Respiratory Disorders||Epistaxis||17 (16)|
|Skin and Subcutaneous Tissue Disorders||Rash Þ||14 (13)|
|Vascular Disorders||Hypertension||12 (11)|
The following adverse reactions with incidence less than 5% were reported in 105 pediatric patients treated with VFEND:
Blood and Lymphatic System Disorders: anemia, leukopenia, pancytopenia
Cardiac Disorders: bradycardia, palpitations, supraventricular tachycardia
Eye Disorders: dry eye, keratitis
Ear and Labyrinth Disorders: tinnitus, vertigo
Gastrointestinal Disorders: abdominal tenderness, dyspepsia
General Disorders and Administration Site Conditions: asthenia, catheter site pain, chills, hypothermia, lethargy
Hepatobiliary Disorders: cholestasis, hyperbilirubinemia, jaundice
Immune System Disorders: hypersensitivity, urticaria
Infections and Infestations: conjunctivitis
Laboratory Investigations: AST increased, blood creatinine increased, gamma-glutamyl transferase increased
Metabolism and Nutrition Disorders: hypercalcemia, hypermagnesemia, hyperphosphatemia, hypoglycemia
Musculoskeletal and Connective Tissue Disorders: arthralgia, myalgia
Nervous System Disorders: ataxia, convulsion, dizziness, nystagmus, paresthesia, syncope
Psychiatric Disorders: affect lability, agitation, anxiety, depression, insomnia
Respiratory Disorders: bronchospasm, nasal congestion, respiratory failure, tachypnea
Skin and Subcutaneous Tissue Disorders: alopecia, dermatitis (allergic, contact, and exfoliative), pruritus
Vascular Disorders: flushing, phlebitis
Hepatic-Related Adverse Reactions in Pediatric Patients
The frequency of hepatic-related adverse reactions in pediatric patients exposed to VFEND in therapeutic studies was numerically higher than that of adults (28.6% compared to 24.1%, respectively). The higher frequency of hepatic adverse reactions in the pediatric population was mainly due to an increased frequency of liver enzyme elevations (21.9% in pediatric patients compared to 16.1% in adults), including transaminase elevations (ALT and AST combined) 7.6% in the pediatric patients compared to 5.1% in adults.
Clinical Laboratory Values in Pediatric Patients
The overall incidence of transaminase increases >3× upper limit of normal was 27.2% (28/103) in pediatric and 17.7% (268/1514) in adult patients treated with VFEND in pooled clinical trials. The majority of abnormal liver function tests either resolved on treatment with or without dose adjustment or after VFEND discontinuation.
A higher frequency of clinically significant liver laboratory abnormalities, irrespective of baseline laboratory values (>3× ULN ALT or AST), was consistently observed in the combined therapeutic pediatric population (15.5% AST and 22.5% ALT) when compared to adults (12.9% AST and 11.6% ALT). The incidence of bilirubin elevation was comparable between adult and pediatric patients. The incidence of hepatic abnormalities in pediatric patients is shown in Table 9.
|n = number of patients with a clinically significant abnormality while on study therapy N = total number of patients with at least one observation of the given lab test while on study therapy AST = Aspartate aminotransferase; ALT = alanine aminotransferase ULN = upper limit of normal|
|Total bilirubin||>1.5× ULN||19/102 (19)|
|AST||>3.0× ULN||16/103 (16)|
|ALT||>3.0× ULN||23/102 (23)|
|Alkaline Phosphatase||>3.0× ULN||8/97 (8)|
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.